marijuana stocks news

Form 8-K for MCIG, INC.

1-Dec-2014

Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets.On November 28, 2014, mCig. announced that it has completed the previously announced spin-off of VitaCig, Inc.. (the “Spin-off”). Effective as of 11:59
p.m., New York City time, on November 28, 2014 (the “Distribution Date”), the Company distributed 270,135,000 shares of common stock of VitaCig, Inc., par value $0.0001 per share (“VitaCig Common Stock”), to holders of mCig’s stockholders of record as a pro rata dividend. The Record Date for the dividend has been set for November 28, 2014 (11/28/2014). This is the official date when a shareholder must be recorded as a shareholder of mCig, Inc. to be eligible for the dividend. The Ex-Dividend Date was set as the close of trading on November 25, 2014. This is due to the logistics of the stock market as US Stock market trades settle T+3 (3 days for settlement of all trades). On the Distribution Date, mCig stockholders received one share of VitCig Common Stock for every one share of common stock, par value $0.0001 per share, of mCig held as of the Record Date. The Spin-off was completed for the purpose of legally and structurally separating VitaCig, Inc. from mCig. MCig retain 230,000,000 shares of common stock and remains as a controlling shareholder. The shares of common stock to be received by mCig shareholders were registered on a Form S-1 filed by VitaCig and declared effective by the Securities and Exchange Commission on November 5, 2014. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Caution Concerning Forward-Looking Statements

This Current Report on Form 8-K includes certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements about the plans, objectives, expectations and intentions of mCig, including the benefits of the Spin-off, and other statements that are not historical facts. These statements are based on the current expectations and beliefs of mCig’s management, and are subject to uncertainty and changes in circumstances. mCig cautions readers that any forward-looking information is not a guarantee of future performance and that actual results may vary materially from those expressed or implied by the statements herein, due to changes in economic, business, competitive, strategic or other regulatory factors, as well as factors affecting the operation of the businesses of mCig and VitaCig. More detailed information about certain of these and other factors may be found in filings by mCig with the Securities and Exchange Commission (the “SEC”). Various factors could cause actual results to differ from those set forth in the forward-looking statements including, without limitation, the risk that the anticipated benefits from the Spin-off may not be fully realized or may take longer to realize than expected. mCig is under no obligation to, and expressly disclaims any obligation to, update or alter the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise.

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$MSRT Accelerates Growth Initiatives as it Launches Updated Business Portal

MassRoots Accelerates Growth Initiatives as it Launches Updated Business Portal and Completes…

$LXRP Announces Million Dollar Research and Development Program

Lexaria Announces Million Dollar Research and Development Program Lexaria Bioscience Corp (LXRP)(CSE:LXX)(LXX.CN)(CNSX:LXX)…

Curaleaf Holdings, Inc. (CURLF) Expands “The Farmer’s Select” Program In Partnership with Autumn Brands

Curaleaf’s Select Brand Expands “The Farmer’s Select” Program In Partnership with Autumn…

INSYS Therapeutics, Inc. (INSY) Announces Results of PK Study

INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations…